PharMerica (PMC -3.5%) takes a hit after Barclays downgrades the stock to Underweight from Equalweight and slashes the price target on the shares to $12 from $16. Analyst Brendan Strong doesn't like the loss of the Kindred contract and cuts his FY14 EPS estimate to $1.10 versus consensus of $1.51.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs